Trial Profile

Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease.

Status: Completed

Phase of Trial: Phase III/IV

Latest Information Update: 07 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Hepatitis A vaccine inactivated; Hepatitis B vaccine recombinant
Indications Diphtheria; Haemophilus infections; Hepatitis A; Hepatitis B; Nosocomial pneumonia; Pneumococcal infections; Pneumonia; Tetanus
Focus Registrational; Therapeutic Use
Acronyms FinIP
Sponsors GlaxoSmithKline; GSK

20 May 2019 Results published in the Vaccine
01 Mar 2018 Results assessing vaccine preventable disease incidence using patient data from NCT00861380 and NCT00839254 trials published in the Vaccine
12 Jul 2017 Results assessing Direct and Indirect Effectiveness of the Ten-Valent Pneumococcal Conjugate Vaccine Against Carriage in three FinIP trials (FinIP, FinIPcarr and FinIP-carriage) published in the Pediatric Infectious Disease Journal

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com